Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
250.71 USD | -0.87% | +2.42% | +45.74% |
11/09 | ResMed Insider Sold Shares Worth $3,646,950, According to a Recent SEC Filing | MT |
06/09 | Resmed Insider Sold Shares Worth $479,800, According to a Recent SEC Filing | MT |
Fiscal Period: June | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 295.7Cr | 319.68Cr | 357.81Cr | 422.3Cr | 468.53Cr | |||||
Total Revenues | 295.7Cr | 319.68Cr | 357.81Cr | 422.3Cr | 468.53Cr | |||||
Cost of Goods Sold, Total | 118.96Cr | 130.74Cr | 151.42Cr | 183.69Cr | 199.7Cr | |||||
Gross Profit | 176.74Cr | 188.95Cr | 206.4Cr | 238.61Cr | 268.83Cr | |||||
Selling General & Admin Expenses, Total | 68Cr | 67Cr | 74Cr | 87Cr | 92Cr | |||||
R&D Expenses | 20Cr | 23Cr | 25Cr | 29Cr | 31Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 7.97Cr | 7.62Cr | 7.07Cr | 7.24Cr | 7.95Cr | |||||
Other Operating Expenses, Total | 96Cr | 97Cr | 106.37Cr | 123.41Cr | 130.41Cr | |||||
Operating Income | 81Cr | 92Cr | 100.03Cr | 115.2Cr | 138.41Cr | |||||
Interest Expense, Total | -4.04Cr | -2.4Cr | -2.23Cr | -4.74Cr | -4.97Cr | |||||
Interest And Investment Income | 10.21L | 4L | - | - | - | |||||
Net Interest Expenses | -3.94Cr | -2.36Cr | -2.23Cr | -4.74Cr | -4.97Cr | |||||
Income (Loss) On Equity Invest. | -2.51Cr | -1.12Cr | -84.86L | -72.65L | -18.48L | |||||
Currency Exchange Gains (Loss) | 13.31L | -8L | - | -42.04L | -1L | |||||
Other Non Operating Income (Expenses) | 10.31L | 10.54L | 31.97L | -15.08L | 7L | |||||
EBT, Excl. Unusual Items | 75Cr | 88Cr | 97Cr | 109.16Cr | 133.31Cr | |||||
Restructuring Charges | - | -1.39Cr | - | -91.77L | -6.42Cr | |||||
Merger & Related Restructuring Charges | - | - | - | -1.09Cr | - | |||||
Gain (Loss) On Sale Of Investments | -1.45Cr | 1.45Cr | -1.22Cr | 99.22L | -40.45L | |||||
Insurance Settlements | - | - | - | 2.02Cr | - | |||||
Legal Settlements | 6L | - | - | - | - | |||||
EBT, Incl. Unusual Items | 73Cr | 88Cr | 96Cr | 110.17Cr | 126.48Cr | |||||
Income Tax Expense | 11Cr | 41Cr | 18Cr | 20Cr | 24Cr | |||||
Earnings From Continuing Operations | 62Cr | 47Cr | 78Cr | 90Cr | 102.1Cr | |||||
Net Income to Company | 62Cr | 47Cr | 78Cr | 90Cr | 102.1Cr | |||||
Net Income - (IS) | 62Cr | 47Cr | 78Cr | 90Cr | 102.1Cr | |||||
Net Income to Common Incl Extra Items | 62Cr | 47Cr | 78Cr | 90Cr | 102.1Cr | |||||
Net Income to Common Excl. Extra Items | 62Cr | 47Cr | 78Cr | 90Cr | 102.1Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 | |||||
Basic EPS - Continuing Operations | 4.31 | 3.27 | 5.34 | 6.12 | 6.94 | |||||
Basic Weighted Average Shares Outstanding | 14Cr | 15Cr | 15Cr | 15Cr | 15Cr | |||||
Net EPS - Diluted | 4.27 | 3.24 | 5.3 | 6.09 | 6.92 | |||||
Diluted EPS - Continuing Operations | 4.27 | 3.24 | 5.3 | 6.09 | 6.92 | |||||
Diluted Weighted Average Shares Outstanding | 15Cr | 15Cr | 15Cr | 15Cr | 15Cr | |||||
Normalized Basic EPS | 3.23 | 3.8 | 4.16 | 4.65 | 5.67 | |||||
Normalized Diluted EPS | 3.21 | 3.77 | 4.13 | 4.63 | 5.65 | |||||
Dividend Per Share | 1.56 | 1.59 | 1.68 | 1.76 | 1.92 | |||||
Payout Ratio | 36.21 | 47.78 | 31.48 | 28.78 | 27.65 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 92Cr | 102.9Cr | 112.44Cr | 129.21Cr | 153.35Cr | |||||
EBITA | 85Cr | 95Cr | 103.55Cr | 119.94Cr | 143.62Cr | |||||
EBIT | 81Cr | 92Cr | 100.03Cr | 115.2Cr | 138.41Cr | |||||
EBITDAR | 95Cr | 106.45Cr | 115.96Cr | 132.57Cr | 157.43Cr | |||||
Total Revenues (As Reported) | 295.7Cr | 319.68Cr | 357.81Cr | 422.3Cr | 468.53Cr | |||||
Effective Tax Rate - (Ratio) | 15.2 | 46.3 | 18.85 | 18.53 | 19.28 | |||||
Current Domestic Taxes | 1.67Cr | -11Cr | 1.51Cr | 5.08Cr | 7.44Cr | |||||
Current Foreign Taxes | 12Cr | 53Cr | 18Cr | 20Cr | 22Cr | |||||
Total Current Taxes | 14Cr | 43Cr | 19Cr | 25Cr | 29Cr | |||||
Deferred Domestic Taxes | -1.63Cr | -2.7Cr | -1.54Cr | -2.41Cr | -2.75Cr | |||||
Deferred Foreign Taxes | -1.35Cr | 1.04Cr | 35.67L | -2.13Cr | -2.23Cr | |||||
Total Deferred Taxes | -2.99Cr | -1.66Cr | -1.18Cr | -4.54Cr | -4.99Cr | |||||
Normalized Net Income | 47Cr | 55Cr | 61Cr | 68Cr | 83Cr | |||||
Interest on Long-Term Debt | 4.04Cr | 2.4Cr | - | 4.74Cr | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 20Cr | 23Cr | 25Cr | 29Cr | 31Cr | |||||
Net Rental Expense, Total | 2.65Cr | 3.55Cr | 3.53Cr | 3.36Cr | 4.08Cr | |||||
Imputed Operating Lease Interest Expense | 66.61L | 65.1L | 73.64L | 1.02Cr | 1.32Cr | |||||
Imputed Operating Lease Depreciation | 1.98Cr | 2.9Cr | 2.79Cr | 2.34Cr | 2.76Cr | |||||
Stock-Based Comp., COGS (Total) | 37.03L | 41.53L | 52.18L | 64.65L | 75.63L | |||||
Stock-Based Comp., R&D Exp. (Total) | 65.91L | 80.47L | 92.48L | 1.16Cr | 1.45Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | 4.73Cr | 5.17Cr | 5.08Cr | 5.3Cr | 5.81Cr | |||||
Total Stock-Based Compensation | 5.76Cr | 6.39Cr | 6.53Cr | 7.11Cr | 8.02Cr |